Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Biochem Pharmacol. 2018 Dec 19;160:134–145. doi: 10.1016/j.bcp.2018.12.014

Fig. 5. Globotriaosylceramide modulates METTL3 and m6A methylation on p53 R273H mutant.

Fig. 5.

A, Representative Western blot. TP53-Dox cells were treated with PDMP (5 μM), FB1 (fumonisin B1, 25 μM), siGb3S (siRNA against Gb3 synthase, 100 nM), STxB (Shiga toxin 1 B subunit, 100 nM), PP2 (Src kinase inhibitor, 500 nM) or FH535 (β-catenin/Tcf inhibitor, 5 μM) for 6 days, with exposure to doxorubicin (100 nM) during the last 48 h of treatments. Equal amounts of detergent-soluble proteins (50 μg/lane) were resolved and then immunoblotted with corresponding antibodies. B, Relative protein levels in TP53-Dox cells with treatments. Protein levels are represented as mean ± SD of their OD values normalized against GAPDH from three settings of blots. *, p<0.001 compared to vehicle. #, p<0.001 compared to PDMP treatment. C, IC50 values for Dox in cells after treatments. TP53-Dox cells were pretreated with PDMP (5 μM), FB1 (25 μM), siGb3S (100 nM), STxB (100 nM), PP2 (10 μM) or FH535 (5 μM) for 48 h, and then co-treated with these agents and various concentrations of Dox for an additional 72 h. *, p<0.001 compared to vehicle control. #, p<0.001 compared to PDMP treatments.